Cosmo Pharmaceuticals N.V - CMOPF

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon. The company also provides Eleview, a submucosal injectable composition for extracting polyps and adenomas; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous lesion detection during colonoscopies; and Aemcolo, a pharmaceutical product used for the treatment of bacterial infections of the colon, such as traveler’s diarrhea, infectious colitis, clostridium difficile associated disease, and diverticulitis, as well as for treatment of inflammatory bowel diseases and hepatic encephalopathy. In addition, it offers Qolotag, a medical device that enhances the detection of lesions during sigmoidoscopies; Remimazolam, an ultra-short-acting sedative/anesthetic. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.